ATE485515T1 - Verfahren zur diagnose einer person mit multipler sklerose - Google Patents

Verfahren zur diagnose einer person mit multipler sklerose

Info

Publication number
ATE485515T1
ATE485515T1 AT02754716T AT02754716T ATE485515T1 AT E485515 T1 ATE485515 T1 AT E485515T1 AT 02754716 T AT02754716 T AT 02754716T AT 02754716 T AT02754716 T AT 02754716T AT E485515 T1 ATE485515 T1 AT E485515T1
Authority
AT
Austria
Prior art keywords
sarg
person
sample
multiple sclerosis
protein
Prior art date
Application number
AT02754716T
Other languages
English (en)
Inventor
Burkhard Jansen
Trevor Lucas
Original Assignee
Burkhard Jansen
Trevor Lucas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burkhard Jansen, Trevor Lucas filed Critical Burkhard Jansen
Application granted granted Critical
Publication of ATE485515T1 publication Critical patent/ATE485515T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AT02754716T 2001-06-22 2002-06-20 Verfahren zur diagnose einer person mit multipler sklerose ATE485515T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29976501P 2001-06-22 2001-06-22
PCT/EP2002/006820 WO2003001212A2 (en) 2001-06-22 2002-06-20 A method for diagnosing a person having multiple sclerosis

Publications (1)

Publication Number Publication Date
ATE485515T1 true ATE485515T1 (de) 2010-11-15

Family

ID=23156198

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02754716T ATE485515T1 (de) 2001-06-22 2002-06-20 Verfahren zur diagnose einer person mit multipler sklerose

Country Status (8)

Country Link
US (1) US7208270B2 (de)
EP (1) EP1407269B1 (de)
JP (1) JP2005500038A (de)
AT (1) ATE485515T1 (de)
AU (1) AU2002321090B2 (de)
CA (1) CA2451351A1 (de)
DE (1) DE60238055D1 (de)
WO (1) WO2003001212A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080160552A1 (en) * 2006-12-13 2008-07-03 Dolly Mehta Methods and Compounds for Treating Inflammation
AU2008210421B2 (en) * 2007-01-30 2014-03-13 Pharmacyclics Llc Methods for determining cancer resistance to histone deacetylase inhibitors
ES2334084B1 (es) 2007-12-21 2011-01-24 Inst Cientifico Tecnol Navarra Marcadores geneticos para el pronostico de la esclerosis multiple.
WO2010014000A1 (en) * 2008-08-01 2010-02-04 Erasmus University Medical Center Rotterdam Susceptibility markers for multiple sclerosis
EP3586866A1 (de) 2018-06-28 2020-01-01 Universität Zürich Immunodominante proteine und fragmente bei multipler sklerose

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158893A (en) * 1986-12-11 1992-10-27 Peralta Cancer Research Institute Methods and compositions for screening carcinomas
ATE244299T1 (de) * 1992-12-18 2003-07-15 Molecular Rx Inc Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
CA2319089A1 (en) * 1998-04-09 1999-10-21 Genset S.A. 5' ests and encoded human proteins
ES2161612B1 (es) * 1999-07-01 2002-06-01 Consejo Superior Investigacion Procedimiento para identificar un compuesto que inhiba la funcion represora de snail.

Also Published As

Publication number Publication date
AU2002321090B2 (en) 2006-11-09
WO2003001212A2 (en) 2003-01-03
EP1407269B1 (de) 2010-10-20
WO2003001212A3 (en) 2003-09-04
DE60238055D1 (de) 2010-12-02
JP2005500038A (ja) 2005-01-06
CA2451351A1 (en) 2003-01-03
EP1407269A2 (de) 2004-04-14
US7208270B2 (en) 2007-04-24
US20030113752A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
ATE530671T1 (de) Verbindungen und verfahren zur diagnose von tuberkulose
ATE275642T1 (de) Verfahren zur diagnose von krebs
DE60239470D1 (de) Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
ATE320505T1 (de) Verfahren zur bestimmung von nukleinsäuresequenzen in urin
TR200000113T2 (tr) Tüberkülozu teşhis etmek için bileşikler ve bunları kullanma yöntemleri.
DE60207979D1 (de) Verfahren und Vorrichtung zur Bestimmung der Gewebespezifität von freier DNA in Körperflüssigkeiten
WO2002057787A3 (en) Detection of survivin in the biological fluids of cancer patients
ATE182216T1 (de) Verfahren zur quantifizierung von lbp in körperflüssigkeiten
WO1998016645A3 (en) Compounds and methods for diagnosis of tuberculosis
ATE283487T1 (de) Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration
WO2000026668A3 (en) S100 proteins and autoantibodies as serum markers for cancer
DE50104561D1 (de) Verfahren zur Diagnose von Sepsis unter Bestimmung löslicher Cytokeratinfragmente
DE50103030D1 (de) Verfahren zur Diagnose von Sepsis unter Bestimmung von S100B
ATE422671T1 (de) Verfahren zur diagnose von morbus alzheimer
DE60238055D1 (de) Verfahren zur diagnose einer person mit multipler sklerose
DE69204157D1 (de) Verfahren zur bestimmung von anti-rns-antikörpern.
ATE173830T1 (de) Verfahren zur bestimmung der quantität extrazellulärer bpi in körperflüssigkeiten
ATE272215T1 (de) Verfahren zur diagnose von sepsis unter bestimmung von ca 19-9
ATE365326T1 (de) Verfahren zur analyse der menge an intraabdominalem fettgewebe
ATE293794T1 (de) Verfahren zur diagnose von sepsis unter bestimmung von ca 125
ATE148233T1 (de) Verfahren zur bestimmung von thrombose verursachenden lupus-anticoagulant-antikörpern
EP0563244A4 (en) Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis
DE59808639D1 (de) Verfahren zur bestimmung von schilddrüsen-autoantikörpern
DE60102245D1 (de) Anhand der konduktivität normalisierte bestimmung von analyten in urin zur diagnose von krankheiten
DE602004022995D1 (de) Verfahren zur diagnose der immunität wiederkehrendren zur behandlung und überwachung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties